RE: More good news23 Sep 2025 07:23
Credibility boost: Prof. Perrie has collaborations with AZ, GSK, Pfizer, MHRA, WHO → putting her name on the programme adds serious scientific legitimacy.
• Validation by association: Academic/industrial partnerships like this are often precursors to commercial traction. Big pharmas don’t like to risk partnering until platforms are well-characterised – CMAC accelerates that process.
• Clinical pathway: N4P is still pre-clinical, and the major criticism has always been: “when will Nuvec actually get into the clinic?” This collaboration directly addresses that gap.
• Dual-loaded vectors: If Nuvec® can show it works with multiple nucleic acid payloads, it broadens licensing opportunities (oncology, vaccines, gene therapy).